...
首页> 外文期刊>Journal of Cancer Research and Therapeutics >Ultrasonography-guided percutaneous radiofrequency ablation for cervical lymph node metastasis from thyroid carcinoma
【24h】

Ultrasonography-guided percutaneous radiofrequency ablation for cervical lymph node metastasis from thyroid carcinoma

机译:超声引导下经皮射频消融治疗甲状腺癌颈淋巴结转移

获取原文
           

摘要

Purpose: The aim was to explore the efficacy and safety of ultrasonography-guided percutaneous radiofrequency ablation (RFA) for cervical lymph node metastases from thyroid carcinoma. Materials and Methods: Eight patients with previous total thyroidectomy and radioiodine therapy were enrolled in this study. A total of 20 cervical lymph node metastases were confirmed by percutaneous biopsy. Participants underwent ultrasonography-guided RFA treatment for all confirmed metastatic lymph nodes. Contrast-enhanced ultrasound (CEUS) and sonoelastography were performed to rapidly evaluate treatment responses before and shortly after RFA. Routine follow-up consisted of conventional US, CEUS, sonoelastography, thyroglobulin level, and necessary fine needle aspiration cytology. Results: All eight patients were successfully treated without obvious complications. Post-RFA CEUS showed that total metastatic lymph nodes were ablated. The sonoelastographic score of ablated area elevated significantly shortly after RFA (P 0.001). With a mean follow-up of 9.4 ± 5.1 months, there were no evidences of recurrence at ablated sites; however, two new cervical recurrent lymph nodes occurred in one case, which was successfully ablated as well. The mass volume shrinkages of the ablated nodes were observed in all cases. We found that 5 treated lymph nodes disappeared, 4 were reduced more than 80%, 9 were reduced between 50% and 80%, and 2 were reduced less than 50%. At the last follow-up evaluation, the serum thyroglobulin levels had decreased in 6 of 8 patients. Conclusion: Ultrasonography-guided percutaneous RFA for cervical lymph node metastasis of thyroid malignancy is a feasible, effective, and safe therapy. This procedure shows a nonsurgical therapeutic option for metastatic lymph nodes in patients with difficult reoperations or inoperations, it may reduce or delay a large number of highly invasive repeated neck dissections.
机译:目的:目的是探讨超声引导下经皮射频消融(RFA)治疗甲状腺癌颈淋巴结转移的疗效和安全性。资料与方法:纳入了8例既往全甲状腺切除术并接受放射性碘治疗的患者。经皮活检证实总共有20个颈淋巴结转移。对所有确诊的转移性淋巴结进行了超声引导的RFA治疗。进行超声造影和超声弹性成像以快速评估RFA之前和之后的治疗反应。常规随访包括常规US,CEUS,超声弹性成像,甲状腺球蛋白水平和必要的细针穿刺细胞学检查。结果:8例患者均获得成功治疗,无明显并发症。 RFA后CEUS显示消融了总的转移淋巴结。射频消融后不久,消融区域的超声弹性图评分显着升高(P <0.001)。平均随访9.4±5.1个月,没有证据显示消融部位复发。但是,有1例发生了2例新的宫颈复发性淋巴结转移,也已成功消融。在所有情况下均观察到消融结节的体积收缩。我们发现,经过治疗的5个淋巴结消失了,4个减少了80%以上,9个减少了50%至80%,2个减少了50%以下。在最后一次随访评估中,8例患者中有6例的血清甲状腺球蛋白水平降低。结论:超声引导下经皮射频消融治疗甲状腺恶性肿瘤的颈部淋巴结转移是一种可行,有效,安全的治疗方法。该程序显示了难以再手术或不手术的患者转移性淋巴结的非手术治疗选择,它可以减少或延迟大量高侵害性重复性颈清扫术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号